Although tremendous efforts in diagnosis and treatment have been made, colorectal cancer (CRC) remains the fourth most common cause of cancer-related death with 1 million new cases and 500 000 deaths worldwide each year ([@bib38]; [@bib10]; [@bib4]). In theory, early stage CRC is cured by surgical resection alone and UICC stage I and II patients are only offered adjuvant chemotherapy in case of risk factors (e.g., intraoperative tumour perforation). UICC stage III patients are routinely recommended adjuvant chemotherapy according to current guidelines ([@bib11]; [@bib16]). However, up to 25% of these patients will develop recurrent disease and current selection criteria for high-risk patients remain insufficient ([@bib38]; [@bib11]; [@bib23]).

The prognostic impact of circulating tumour cells (CTC) in the blood of patients with CRC has been studied extensively and was recently confirmed by a meta-analysis ([@bib24]). However, different non-standardised detection methods of CTC have made inter-study comparisons difficult, and only limited data exists about the prognostic role of CTC in patients with early stage CRC ([@bib14]; [@bib12], [@bib13]; [@bib17]; [@bib3]; [@bib29]; [@bib37]; [@bib36]; [@bib20]; [@bib39]; [@bib18]; [@bib33]; [@bib34]). The Food and Drug Administration has approved the CellSearch system for CTC monitoring in patients with metastatic colorectal, prostate and breast cancers ([@bib6], [@bib7], [@bib8]; [@bib22]; [@bib30]). Introduction of this semi-automatic assay allows for detection and enumeration of CTC in a standardised fashion. However, data on CTC as a predictive and prognostic marker in CRC patients have so far been exclusively available for patients with metastatic disease. Recently, it has been reported that detection of CTC in the blood of patients with non-metastatic breast cancer is an independent prognostic marker for overall and progression-free survival (OS and PFS, respectively) ([@bib19]).

It was the aim of the present prospective study to evaluate the prognostic value of CTC measured by the CellSearch system in patients with potentially curable disease, focussing on non-metastatic CRC.

Methods
=======

Reporting of the present study was in accordance with the REMARK guidelines ([@bib21]).

Patients
--------

Patients with UICC stage I--IV CRC who underwent surgery with curative intent at the Department of General, GI and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany between May 2009 and August 2012 were included in this study. In addition to patients with non-metastatic CRC (UICC I--III group), patients with limited, synchronous metastases were eligible for inclusion if their operation was done with curative intent and no macroscopic tumour (primary CRC and metastases) remained after surgery (UICC I--IV group). Patients were deemed ineligible if they refused participation, presented with unresectable CRC and/or liver metastases or had a history of any other malignancy during the past 5 years. Written informed consent was obtained prior to surgery. The study was approved by the ethics committee of the University of Heidelberg (323/3004). Details about our management of patients with primary CRC and colorectal liver metastases have been reported elsewhere ([@bib28]; [@bib25]). Adjuvant treatment was done according to current treatment guidelines after obtaining interdisciplinary consensus for each patient.

Blood sample collection and CTC detection
-----------------------------------------

TNM cancer staging was in accordance with the criteria set by the American Joint Commission on Cancer ([@bib1]). Blood samples from the central venous blood or from the peripheral blood were taken immediately prior to surgical incision after induction of general anaesthesia for all patients in the operating room. CTC detection in the central venous blood compartment is similar to the cell count obtained from peripheral blood, which has been validated by us in previous studies. Blood samples were drawn into and immediately transferred to cell preservative tubes (CellSave, Veridex LLC, Raritan, NJ, USA). Isolation of CTC with the CellTracks Autoprep System (Veridex LLC) and semi-automatic analysis via the CellTracks Analyzer II system (Veridex LLC) have been described previously ([@bib2]; [@bib25]). Two trained operators blinded to patient\'s data screened results independently, and differences in CTC count were resolved by discussion. All results for individual patients were masked from the analysing investigators by using a number system as a unique patient identifier. Operators of the CellSearch system were blinded for clinicopathological data of patient samples.

Blood samples were only analysed for patients, and no control group with healthy volunteers or patients with benign disease were included in this trial. CTC count in healthy volunteers has been studied extensively for the validation purposes of the CellSearch system ([@bib2]; [@bib9]; [@bib22]). CTC detected by the CellSearch technique are extremely rare in healthy volunteers (\<3.5% for a threshold ⩾1 CTC per 7.5 ml blood) and patients with benign disease (\<7.5% for a threshold of ⩾1 CTC per 7.5 ml blood) ([@bib22]). A control group was not included as it would not have added any substantial information to the aim of the present study.

Statistical analyses
--------------------

All analyses were carried out separately for patients with non-metastatic CRC (UICC I--III group) and the entire cohort (UICC I--IV group). Patients with complete pathological response (T0, N0, M0) were included in the UICC I--III group. Categorical data were presented as absolute and relative frequencies. Continuous data were presented as median and range. For CTC data, the arithmetic mean and s.e.m. (s.d.) were reported. The association of CTC detection with clinicopathological variables was evaluated using the *χ*^*2*^-test. The primary end point of the present study was OS, which was calculated from the date of surgery to the date of death due to any cause or the date of last follow-up information. Progression-free survival was defined as time from the date of surgery until objective tumour progression or death. Survival curves were constructed according to the Kaplan--Meier method and compared using the log-rank test. As limited data were available on cutoff levels for the number of CTC to determine tumour cell-positive patients, all analyses were carried out for three cutoffs, that is, ⩾1 CTC, ⩾2 CTC and ⩾3 CTC. Variables that had significant associations with CTC detection on univariate analyses were included in multivariate analyses using Cox proportional hazards regression methodology. A *P-*value ⩽0.05 was considered to indicate a statistically significant difference. All *P*-values were two-sided. Statistical analyses were done with the SPSS software version 19 (SPSS, Chicago, IL, USA) and JMP program version 7 (SAS Institute Inc., Cary, NC, USA).

Results
=======

A total of 287 Patients with resectable CRC who underwent potentially curative therapy were included in this study, including 239 patients with non-metastatic disease (UICC stage I--III). Forty-eight patients underwent resection for CRC with synchronous metastases with curative intent. In the UICC stage I--III group, 157 male (65.7%) and 82 female (34.3%) patients were included; in the UICC stage I--IV group, there were 186 male (64.5%) and 101 female patients (35.2%). The majority of patients with metastatic disease had liver metastases, whereas metastases in the lungs and other locations were present in 6 (12.5%) and 7 (14.6%) patients, respectively. Three (6.2%) patients had multiple sites of metastases ([Table 1](#tbl1){ref-type="table"}).

Detection rate of CTC in CRC is stage dependent
-----------------------------------------------

In the analysis of preoperative blood samples, ⩾1 CTC per 7.5 ml of blood were found in 30 patients (10.5%), ⩾2 CTC in 9 patients (3.1%) and ⩾3 more CTC in 5 patients (1.7%) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Detection rate of CTC was significantly correlated with the stage of disease comparing non-metastatic and metastatic patients with 3 (4.9%), 9 (10.5%), 7 (8.3%) and 9 (18.8%) patients with ⩾1 detected CTC in UICC stages I, II, III and IV, respectively (*P*=0.03). The stage-dependent CTC detection with increased detection rates for patients with UICC IV disease was confirmed for detection of ⩾2 (*P*=0.001) or ⩾3 (*P*=0.008) CTC per 7.5 ml of blood ([Figure 1](#fig1){ref-type="fig"}). Furthermore, patients\' stage of disease was associated significantly with the number of CTC in peripheral blood detected intraoperatively. Postoperative blood samples with CTC analyses on postoperative days 3 and 7 were carried out in 51 and 28 patients, respectively. In the UICC I--III group ⩾1 CTC was detected on postoperative days 3 and 7 in 4 (10.0%) and 3 (14.3%) patients, whereas in the UICC stage I--IV group 9 (17.6%) and 6 (21.4%) patients had detectable CTC.

Lack of association of primary tumour characteristics with CTC detection in non-metastatic CRC
----------------------------------------------------------------------------------------------

The association of various clinicopathological characteristics with preoperative presence of CTC in the systemic circulation was analysed for three different cutoff values of CTC detection. No primary tumour characteristics or clinicopathological parameters predicted the presence of CTC for the non-metastatic (UICC stage I--III) group ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). There was, however, a trend towards higher detection rates in patients who had received any kind of neoadjuvant therapy (*P*=0.07) and a trend towards increased CTC detection in patients with locally advanced tumours (T3/4 *vs* T1/2; *P*=0.14). To further elucidate whether a certain kind of neoadjuvant therapy caused an increase in CTC, we performed further subgroup analyses. These revealed a significantly higher CTC detection rate in non-metastatic patients with neoadjuvant chemoradiotherapy (*P*=0.002). This association remained statistically significant for the entire study cohort, including patients with stage IV disease (*P*=0.03).

The analyses of the entire study group confirmed the significantly higher presence of CTC in patients with metastatic disease compared with non-metastatic patients (*P*=0.04). In addition, preoperative CEA level (*P*=0.03) and CA 19-9 level (*P*=0.01) were significantly associated with detection of ⩾1 CTC per 5 ml of blood in patients with UICC I--IV disease ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). The association of T stage and CTC detection failed to reach statistical significance in these patients (*P*=0.08).

Presence of CTC is a strong and independent predictor of OS and PFS in patients with non-metastatic CRC
-------------------------------------------------------------------------------------------------------

The mean follow-up time was 28 (0--53) months. During the follow-up period, 22 (9.2%) patients died and 23 (9.6%) patients were diagnosed with disease progression in the UICC I--III group. In the complete study group, 40 (13.9%) patients died and 45 (15.7%) patients had disease progression during follow-up ([Figure 2](#fig2){ref-type="fig"}).

To evaluate the prognostic value of preoperative CTC detection on OS and PFS in patients with non-metastatic CRC, univariate analyses were performed initially to evaluate known prognosticators in the present study cohort. In patients with non-metastatic disease, age (*P*=0.036) was associated with significantly shorter OS, whereas T stage (*P*=0.029) and N status (*P*=0.002) were predictors of poor PFS. Patients with non-metastatic disease who were found to have ⩾1 CTC per 7.5 ml blood preoperatively had significantly shorter OS (*P*\<0.001) and PFS (*P*\<0.001) on univariate analyses ([Table 2](#tbl2){ref-type="table"}). This association was also confirmed for the preoperative detection of ⩾2 and ⩾3 CTC (data not shown). Furthermore, the adverse prognostic impact of detection of ⩾1 CTC on OS (*P*\<0.001) and PFS (*P*\<0.001) was confirmed for the cohort of 158 patients who had no neoadjuvant treatment ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Identification of patients with node-negative disease who are at risk for disease recurrence remains a clinical challenge. Our study population included 155 patients with node-negative CRC who had no evidence of distant metastases at the time of diagnosis. Of these, 14 (9%) had ⩾1 CTC per 7.5 ml blood preoperatively. These patients had significantly worse OS (34.1 *vs* 50.4 months; *P*=0.001) and PFS (30.8 *vs* 50.6 months; *P*\<0.001).

On multivariate analyses, preoperative detection of ⩾1 CTC per 7.5 ml blood was confirmed as a strong and independent predictor of OS (HR 5.5; 95% CI 2.3--13.6; *P*\<0.001) and PFS (HR 12.7; 95% CI 5.2--31.1; *P*\<0.001) in patients with UICC stage I--III disease.

The analyses of the entire study cohort, including patients with UICC stage I--IV disease, revealed patients\' age (*P*=0.04), N status (*P*=0.001), presence of distant metastases (*P*\<0.001), elevated preoperative CEA level (*P*=0.001) and elevated preoperative CA 19-9 level (*P*\<0.001) to be associated with significantly impaired OS, whereas a significant association with shortened PFS was found for patients\' T stage (*P*=0.005), N stage (*P*\<0.001), presence of distant metastases (*P*\<0.001), elevated preoperative CEA level (*P*=0.001) and elevated preoperative CA 19-9 level (*P*\<0.035) ([Table 3](#tbl3){ref-type="table"}). Patients with ⩾1 CTC per 7.5 ml blood preoperatively had significantly worse OS (*P*\<0.001) and PFS (*P*\<0.001). A strong association of preoperative CTC detection and OS well as PFS was also found for a cutoff of ⩾2 and ⩾3 CTC per 7.5 ml blood preoperatively. After exclusion of patients with neoadjuvant therapy, CTC detection was still associated with poor OS (*P*\<0.001) and PFS (*P*\<0.001).

In these patients, ⩾1 CTC per 7.5 ml blood was associated with poor OS (*P*\<0.001) and PFS (*P*\<0.001). This association was confirmed for the preoperative detection of ⩾2 and ⩾3 CTC per 7.5 ml blood. In addition, age (*P*=0.036) was associated with poor OS, whereas T stage (*P*=0.029) and N status (*P*=0.002) were predictors of poor PFS in these patients with non-metastatic disease.

On multivariate analyses, including all variables with significant associations on univariate analyses, presence of ⩾1 CTC was revealed as an independent predictor of OS (HR 5.6; 95% CI 2.6--12.0; *P*\<0.001) and PFS (HR 7.8; 95% CI 3.9--15.5; *P*\<0.001). Remarkably, the prognostic impact of preoperative CTC detection was independent of the presence of distant metastases, which was revealed as a further independent prognostic factor of OS (HR 2.3; 95% CI 1.0--5.0; *P*=0.035) and PFS (HR 7.8; 95% CI 3.9--15.5; *P*=0.002) ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

In the present study, we investigated whether preoperative detection of CTC in the systemic circulation can serve as a prognostic biomarker in CRC patients without distant metastases or with limited metastatic disease amenable to curative resection. Although we have previously demonstrated a prognostic value of CTC in patients with primary CRC in a meta-analysis, the included studies varied considerably with respect to the methods of CTC detection. Indeed, the predictive and prognostic value of CTC using standardised assays has only been demonstrated and validated for advanced metastatic CRC ([@bib7], [@bib8]; [@bib31]). A recently published study from the MD Anderson Cancer Center revealed CTC detected by the CellSearch system as an independent prognostic marker for OS and PFS in patients with non-metastatic breast cancer ([@bib19]).

Here we show for the first time that preoperative CTC detection using the standardised CellSearch system is a strong and independent prognostic factor for disease progression and survival in non-metastatic CRC patients. Interestingly, the detection of CTC preoperatively did not correlate with any other clinicopathological factor in patients with non-metastatic disease. As we did not find any association between CTC detection and clinical parameters, this suggests CTC detection as an independent indicator of aggressive tumour biology in our patients, in line with the findings of [@bib19] in non-metastasised breast-cancer patients. In line with these findings, the detection of CTC in UICC stage I--III patients proofed to be the strongest predictor of OS and PFS, considering known prognostic factors, such as age or lymph node status. Collectively, these data suggest CTC as a potentially useful prognostic and predictive biomarker in non-metastatic CRC patients that may help to further stratify patient\'s risk status within different stages of disease. Furthermore, this should prompt further studies to dissect the molecular mechanisms of tumour cell dissemination.

The CellSearch system enables the detection as well as enumeration of CTC. Previous studies have suggested different cutoff levels to determine 'CTC positivity\'. [@bib2] evaluated the CellSearch system in a study of 964 patients. Based on the mean CTC count in healthy subjects, these authors suggested the detection of ⩾2 CTC per 7.5 ml of blood as abnormal. Using a training and validation set of patients with metastatic CRC, [@bib7], [@bib8]) defined unfavorable prognostic groups by detection of ⩾3 CTC per 7.5 ml of blood. All patients in these studies had metastatic disease, we report here the largest study of patients with non-metastatic CRC studied with the CellSearch system so far and the first to evaluate its prognostic value in these patients. Our results show a significantly lower detection rate of CTC in patients with non-metastatic CRC. Based on the relatively low proportion of patients with ⩾1 CTC per 7.5 ml blood who had a significantly worse outcome compared with patients without CTC, we recommend that risk stratification of non-metastatic CRC patients should be done at a threshold of ⩾1 CTC.

Adjuvant therapy in patients with node-negative CRC remains a controversial issue. Evidence from recent studies suggests that patients\' selection for adjuvant therapy based on clinical factors might be inaccurate and molecular markers might be useful ([@bib23]; [@bib26], [@bib27]). Our study demonstrates that the CellSearch system provides prognostic information in CRC patients with UICC stage I/II disease and confirms previous data using CTC detection by CK20 PCR ([@bib15]). These data suggest that detection of CTC using standardised assays should be considered to improve current staging of patients (i.e., cM0(i+)) and the selection of patients for adjuvant chemotherapy. However, several issues need to be addressed before integration of CTC detection into the TNM classification and treatment guidelines. First, our results on patients with non-metastatic CRC need to be validated in further cohorts from different institutions. Second, there is no proof so far that adjuvant therapy improves long-term outcome of patients with cM0(i+) disease. We recently showed that preoperative risk status using clinical parameters can predict efficacy of adjuvant chemotherapy after resection of CRC liver metastases ([@bib27]). A randomised controlled trial would be needed to achieve level I evidence on the benefit of adjuvant therapy in CRC patients with cM0(i+) disease. However, such a trial will be almost impossible to perform owing to the low CTC detection rate in this group of patients, and an international patient registry might offer an alternative strategy to provide valuable information. Third, detection of CTC using the CellSearch technique is only investigating a subgroup of CM0(i+) patients. The CellSearch technique only detects CTC in the blood, which are positive for EPCAM and cytokeratin. However, there is evidence that not all CTC are positive for these markers, and it remains subject of future studies to evaluate the prognostic and predictive value of other CTC detection assays capturing a broader spectrum of CTC populations ([@bib32]). Furthermore, the clinical value of tumour cell detection in further body compartments such as the bone marrow, regional lymph nodes and mesenteric blood needs to be clarified to determine which compartment provides the most accurate information on patients\' outcome ([@bib26], [@bib25]).

Interestingly, even though CTC detection *per se* is a strong indicator of survival and disease burden, it remains unclear whether detected CTC are actually precursors of metastatic lesions (and possess the ability to form distant metastases) or whether CTC originate from metastases (or the primary tumour) and are just a measurement of overall disease burden. The molecular characterisation of single CTC will be an important step forward to answer these questions and to ultimately use CTC as liquid biopsies during different stages of disease progression for treatment decisions and monitoring purposes ([@bib35]; [@bib5]).

In conclusion, our study provides promising results for the use of CTC as a prognostic and predictive biomarker in patients with non-metastatic CTC. The lack of association between CTC detection and clinical parameters suggests CTC as an independent indicator of aggressive tumour biology. This should clearly be followed in larger trials with longer follow-up times. Our results warrant further validation within larger multi-institutional trials to test and clarify whether detection of CTC in the blood should be included into current treatment guidelines of non-metastatic CRC.
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![**Detection rate and count of CTC.** (**A**--**C**) Stage-dependent detection rate of CTC with a threshold of ⩾1 (**A**), ⩾2 (**B**) and ⩾3 (**C**) CTC. (**D**) Stage-dependent detection count of CTC. (**E** and **F**) Perioperative detection of ⩾1 CTC in UICC stage I--III (**E**) and stage I--IV (**F**) patients.](bjc201588f1){#fig1}

![**Overall survival and progression-free survival according to presence of at least 1 CTC stratified for the stage of disease.** (**A**--**C**) Kaplan--Meier estimates of overall survival in patients with UICC stage I--II (**A**), stage I--III (**B**) and stage I--IV (**C**) disease. (**D**--**F**) Kaplan--Meier estimates of progression-free survival in patients with UICC stage I--II (**D**), stage I--III (**E**) and stage I--IV (**F**) disease.](bjc201588f2){#fig2}

###### Clinicopathological characteristics of the study population

                                    **Stage I--III (*****n*****=239)**   **Stage I--IV (*****n*****=287)**
  -------------------------------- ------------------------------------ -----------------------------------
  Age                                          64 (27--96)                          64 (27--96)
  **Sex**                                                               
  Male                                          157 (65.7)                          186 (64.5)
  Female                                        82 (34.3)                           101 (35.2)
  **Site of disease**                                                   
  Colon                                         102 (42.7)                          134 (46.7)
  Rectum                                        137 (57.3)                          153 (53.3)
  **T stage**                                                           
  T0                                             6 (2.5)                              6 (2.1)
  T1                                             18 (7.5)                            20 (7.0)
  T2                                            63 (26.4)                            65 (22.6)
  T3                                            131 (54.8)                          161 (56.1)
  T4                                             21 (8.8)                            35 (12.2)
  **N Stage**                                                           
  N0                                            155 (64.9)                          170 (59.2)
  N1                                            59 (24.7)                            76 (26.5)
  N2                                            25 (10.5)                            41 (14.3)
  **Resection margins**                                                 
  R0                                            223 (97.4)                          262 (96.3)
  R1                                             6 (2.6)                             10 (3.7)
  Tumour height (cm)                           7.3 (0--18)                          7.4 (0--18)
  **Distribution of metastases**                                        
  Liver                                            ---                               32 (66.7)
  Lung                                             ---                               6 (12.5)
  Other                                            ---                               7 (14.6)
  Multiple sites                                   ---                                3 (6.2)
  Neoadjuvant therapy                           81 (33.9)                            95 (33.1)
  Neoadjuvant radiation                         81 (33.9)                            87 (30.0)
  Adjuvant therapy                              57 (36.5)                            83 (43.7)
  Follow-up (months)                            28 (0--53)                          28 (0--53)
  CEA (\>2.5 U l^−1^)                            54 (24)                             87 (32.0)
  CA 19-9 (\>37 U l^−1^)                        24 (10.7)                            39 (14.3)

Abbreviation: CEA=carcinoembryonic antigen.

###### Univariate analyses of factors associated with overall survival and progression-free survival in non-metastatic CRC (UICC I--III)

                                                **Overall survival**   **Progression-free survival**                      
  -------------------------------------------- ---------------------- ------------------------------- ------------------- ---------
  **Gender**                                                                                                              
  Male                                           47.9 (45.7--50.2)                 0.220               47.7 (45.4--50.1)    0.356
  Female                                         50.4 (48.0--52.8)                                     49.6 (46.8--52.4)       
  **Age (years)**                                                                                                         
  \<65                                           50.4 (48.5--52.3)                 0.036               49.1 (46.7--51.4)    0.305
  ⩾65                                            47.2 (44.5--50.0)                                     47.6 (44.8--50.4)       
  **T stage**                                                                                                             
  T 1/2                                          49.8 (47.6--52.1)                 0.228               50.7 (48.7--52.7)    0.029
  T 3/4                                          48.2 (44.8--50.5)                                     46.9 (44.3--49.5)       
  **N stage**                                                                                                             
  N0                                             49.7 (47.7--51.6)                 0.294               49.8 (47.8--51.7)    0.002
  N1                                             48.1 (44.4--51.8)                                     48.8 (47.8--51.7)       
  N2                                             36.0 (31.1--41.0)                                     31.2 (24.8--37.6)       
  **R status**                                                                                                            
  R0                                             49.4 (47.7--51.1)                 0.069               48.6 (46.8--50.5)    0.28
  R1                                             37.7 (21.6--53.7)                                     44.6 (30.4--58.9)       
  **Site of primary tumour**                                                                                              
  Colon                                          49.5 (47.1--51.9)                 0.510               49.3 (46.7--51.9)    0.431
  Rectum                                         48.2 (45.9--50.6)                                     47.7 (45.2--50.2)       
  **Stage of disease**                                                                                                    
  UICC I--III                                           ---                                                   ---              
  UICC I--IV                                            ---                                                   ---              
  **CEA level (*****μ*****g l**^**−1**^)                                                                                  
  \<2.5                                          49.2 (47.6--51.1)                 0.739               49.1 (47.1--51.0)    0.447
  ⩾2.5                                           48.6 (44.7--52.4)                                     47.5 (43.2--51.8)       
  **CA 19-9 level (*****μ*****g l**^**−1**^)                                                                              
  \<37                                           49.0 (47.2--50.8)                 0.970               48.9 (47.0--50.7)    0.541
  ⩾37                                            49.2 (43.8--54.5)                                     47.2 (40.8--53.6)       
  **Neoadjuvant therapy**                                                                                                 
  Yes                                            49.7 (47.8--51.6)                 0.138               49.2 (47.1--51.3)    0.288
  No                                             47.2 (43.8--50.5)                                     46.9 (43.3--50.4)       
  **CTC⩾1**                                                                                                               
  No                                             49.8 (48.3--51.4)                \<0.001              50.1 (48.6--51.6)   \<0.001
  Yes                                            38.4 (29.4--47.4)                                     30.8 (20.8--40.8)       
  **CTC⩾2**                                                                                                               
  No                                             49.3 (47.6--51.0)                 0.003               48.9 (47.1--50.6)    0.003
  Yes                                             28.4 (8.7--48.1)                                     27.4 (6.9--47.9)        
  **CTC⩾3**                                                                                                               
  No                                             49.1 (47.4--50.8)                 0.021               48.7 (46.9--50.5)    0.016
  Yes                                             25.6 (0--56.8 )                                      25.3 (0.0--56.9)        

Abbreviations: CI=confidence interval; CEA=carcinoembryonic antigen; CTC=circulating tumour cells; UICC=Union for International Cancer Control.

###### Univariate analyses of factors associated with overall survival and progression-free survival in the complete study cohort (UICC I--IV)

                                                **Overall survival**   **Progression-free survival**                      
  -------------------------------------------- ---------------------- ------------------------------- ------------------- ---------
  **Gender**                                                                                                              
  Male                                           46.7 (44.2--48.9)                 0.960               44.9 (42.4--47.5)    0.536
  Female                                         47.0 (43.9--50.0)                                     46.4 (43.1--49.7)       
  **Age (years)**                                                                                                         
  \<65                                           48.3 (46.1--50.5)                 0.044               45.1 (42.2--47.9)    0.909
  ⩾65                                            45.0 (42.2--47.8)                                     45.7 (42.8--48.6)       
  **T stage**                                                                                                             
  T 1/2                                          48.2 (45.5--50.9)                 0.178               49.3 (46.9--51.8)    0.005
  T 3/4                                          46.0 (43.7--48.4)                                     43.5 (40.7--46.2)       
  **N stage**                                                                                                             
  N0                                             49.2 (47.2--51.1)                 0.001               48.6 (46.5--50.8)   \<0.001
  N1                                             45.1 (41.4--48.9)                                     43.4 (39.1--47.7)       
  N2                                             37.6 (31.9--43.3)                                     34.1 (27.5--40.6)       
  **R status**                                                                                                            
  R0                                             47.4 (45.5--49.2)                 0.064               45.7 (43.6--47.9)    0.368
  R1                                             36.9 (25.4--48.4)                                     37.7 (23.9--51.4)       
  **Site of primary tumour**                                                                                              
  Colon                                          45.9 (43.2--48.7)                 0.333               45.5 (42.5--48.5)    0.986
  Rectum                                         47.5 (45.2--49.9)                                     45.4 (42.6--48.1)       
  **Stage of disease**                                                                                                    
  UICC I--III                                    48.7 (47.0--50.5)                \<0.001              48.5 (46.7--50.4)   \<0.001
  UICC I--IV                                     38.2 (33.0--43.4)                                     30.3 (23.8--36.8)       
  **CEA level (*****μ*****g l**^**−1**^)                                                                                  
  \<2.5                                          49.1 (47.3--51.0)                 0.001               48.1 (46.0--50.2)    0.001
  ⩾2.5                                           42.5 (38.4--46.5)                                     40.5 (36.0--45.1)       
  **CA 19-9 level (*****μ*****g l**^**−1**^)                                                                              
  \<37                                           48.2 (46.5--50.0)                 0.000               46.5 (44.4--48.6)    0.035
  ⩾37                                            39.3 (33.0--45.7)                                     40.4 (33.5--47.2)       
  **Neoadjuvant therapy**                                                                                                 
  No                                             47.0 (44.9--49.2)                 0.852               46.5 (44.1--48.8)    0.229
  Yes                                            46.6 (43.3--49.8)                                     43.6 (39.7--47.5)       
  **CTC⩾1**                                                                                                               
  No                                             48.4 (46.7--50.0)                \<0.001              47.9 (46.0--49.7)   \<0.001
  Yes                                            33.6 (26.3--41.0)                                     25.6 (17.6--33.6)       
  **CTC⩾2**                                                                                                               
  No                                             47.5 (45.7--49.2)                \<0.001              46.5 (44.6--48.5)   \<0.001
  Yes                                            28.3 (16.4--40.2)                                     16.3 (5.0--27.6)        
  **CTC⩾3**                                                                                                               
  No                                             47.2 (45.5--49.0)                 0.001               46.1 (44.1--48.1)   \<0.001
  Yes                                             24.7 (7.7--41.8)                                     14.0 (0.0--29.2)        

Abbreviations: CI=confidence interval; CEA=carcinoembryonic antigen; CTC=circulating tumour cells; UICC=Union for International Cancer Control.

###### Cox proportional hazards models for overall survival and progression-free survival

  **Variable**                      **Comparison**    **Hazard ratio**   **95% CI**   ***P*****-value**
  ------------------------------- ------------------ ------------------ ------------ -------------------
  **UICC Stage I--III**                                                              
  **Overall survival**                                                                         
   Age (years)                       ⩾65 *vs*\<65           2.7           1.0--7.0          0.037
   CTC                                ⩾1 *vs* 0             5.5          2.3--13.6         \<0.001
  **Progression-free survival**                                                                
   N stage                                N0                                                0.003
                                          N1                1.4           0.5--4.3          0.510
                                          N2                6.2          2.1--18.2          0.001
   T stage                         T 3/4 *vs* T 1/2         1.7           0.5--5.4          0.368
   CTC                                ⩾1 *vs* 0             12.7         5.2--31.1         \<0.001
  **UICC Stage I--IV**                                                               
  **Overall survival**                                                                         
   Age (years)                       ⩾65 *vs*\<65           2.9           1.4--6.2          0.005
   N stage                                N0                                                0.107
                                          N1                1.6           0.7--3.8          0.247
                                          N2                2.5           1.0--5.9          0.035
   Stage of disease                UICC IV *vs* III         2.3           1.0--5.0          0.035
   CEA level (*μ*g l^−1^)          ⩾2.5 *vs* \<2.5          1.5           0.6--3.3          0.372
   CA 19-9 level (*μ*g l^−1^)       ⩾37 *vs* \<37           1.3           0.6--2.9          0.548
   CTC                                ⩾1 *vs* 0             5.6          2.6--12.0         \<0.001
  **Progression-free survival**                                                                
   T stage                         T 3/4 *vs* T 1/2         2.0           0.7--5.6          0.177
   N stage                                N0                                                0.129
                                          N1                1.2           0.5--2.6          0.688
                                          N2                2.3           1.0--5.4          0.059
   Stage of disease                UICC IV *vs* III         3.3           1.5--7.2          0.002
   CEA level (*μ*g l^−1^)          ⩾2.5 *vs* \<2.5          1.2           0.6--2.8          0.558
   CA 19-9 level (*μ*g l^−1^)       ⩾37 *vs* \<37           0.7           0.3--1.5          0.347
   CTC                                ⩾1 *vs* 0             7.8          3.9--15.5         \<0.001

Abbreviations: CI=confidence interval; CEA=carcinoembryonic antigen; CTC=circulating tumour cells; UICC=Union for International Cancer Control.

[^1]: These authors contributed equally to this work.
